News Website

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.

Read Full Article

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.

Read Full Article

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.

Read Full Article

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer 2 Minute Medicine

Published: March 17, 2025, 11:07 p.m.

Read Full Article

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer - OncLive

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer OncLive

Published: March 17, 2025, 9:22 p.m.

Read Full Article

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer - OncLive

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer OncLive

Published: March 6, 2025, 2:32 p.m.

Read Full Article

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com

Published: March 5, 2025, 11:04 a.m.

Read Full Article

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer - Oncology Nurse Advisor

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer Oncology Nurse Advisor

Published: March 5, 2025, 5 a.m.

Read Full Article

Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer - Frontiers

Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer Frontiers

Published: March 4, 2025, 1:24 p.m.

Read Full Article

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.

Read Full Article

Latest Articles

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer - 2 Minute Medicine

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer - OncLive

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer - OncLive

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Short-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial Cancer - Oncology Nurse Advisor

Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer - Frontiers

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Subscribe to Our Newsletter